Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial

Published:2020-05 Issue:10234 Volume:395 Page:1434-1443
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Tricou Vianney,Sáez-Llorens Xavier,Yu Delia,Rivera Luis,Jimeno José,Villarreal Ana Cecilia,Dato Epiphany,Saldaña de Suman Onix,Montenegro Nathali,DeAntonio Rodrigo,Mazara Sonia,Vargas Maria,Mendoza Debbie,Rauscher Martina,Brose Manja,Lefevre Inge,Tuboi Suely,Borkowski Astrid,Wallace Derek

Publisher

Elsevier BV

Subject

General Medicine

Reference21 articles.

1. Severe dengue in travellers: pathogenesis, risk and clinical management;Halstead;J Travel Med,2019

2. The global distribution and burden of dengue;Bhatt;Nature,2013

3. Antibody-dependent enhancement of severe dengue disease in humans;Katzelnick;Science,2017

4. Role of antibodies in controlling dengue virus infection;van der Schaar;Immunobiology,2009

5. Effect of dengue serostatus on dengue vaccine safety and efficacy;Sridhar;N Engl J Med,2018

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial;Vaccine;2024-12

2. Identification and functional analysis of C-type lectin from mosquito Aedes albopictus in response to dengue virus infection;Parasites & Vectors;2024-09-04

3. Increased number of dengue fever cases in the United States of America and its territories in 2024;Journal of Medical Virology;2024-08

4. Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis;Vaccines;2024-07-13

5. Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group;Clinical Infectious Diseases;2024-07-12